Value-based differential pricing: Efficient prices for drugs in a global context

Health Economics (United Kingdom)

Volumn 24, Issue 3, 2015, Pages 294-301

  Danzon, Patricia ^a   Towse, Adrian ^b   Mestre Ferrandiz, Jorge ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OFFICE OF HEALTH ECONOMICS   (United Kingdom)

Author keywords

Differential pricing; ICER thresholds; Value based pricing

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG QUALITY; DRUG UTILIZATION; HEALTH INSURANCE; INTERNATIONAL COOPERATION; LAW; POLICY; PRIORITY JOURNAL; REIMBURSEMENT; COMMERCIAL PHENOMENA; ECONOMIC ASPECT; ECONOMICS; ORGANIZATION AND MANAGEMENT; STATISTICS AND NUMERICAL DATA;

COMMERCE; DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; INSURANCE, PHARMACEUTICAL SERVICES;

EID: 84922219447     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3021     Document Type: Article

References (17)

1. Barros P, Martinez-Giralt X. 2008. On international cost-sharing of pharmaceutical R&D. International Journal of Health Care Finance and Economics 8: 301-312.
2. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. 2008. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336: 251-254.
3. Danzon P. 1997. Price discrimination for pharmaceuticals: welfare effects in the US and EU. International Journal of the Economics of Business 4(3): 301-321.
4. Danzon P, Taylor E. 2010. Drug pricing and value in oncology. The Oncologist 15(1): 24-31.
5. Danzon P, Towse A. 2003. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics 3: 183-205.
6. Danzon P, Mulcahy A, Towse A. 2011. Pharmaceutical prices in emerging markets: effects of income, competition and procurement. NBER Working Paper 17174. Cambridge, MA.
7. Danzon P, Towse A, Mestre-Ferrendiz J. 2012. Value-based differential pricing: efficient prices for drugs in a global context. NBER Working Paper No. 18593. Cambridge, MA.
8. Flynn S, Hollis A, Palmedo M. 2009. An economic justification for open access to essential medicine patents in developing countries. The Journal of Law, Medicine & Ethics 37(2): 184-208.
9. Garber A, Phelps C. 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16: 1-31.
10. Garber A, Jones C, Romer P. 2006. Insurance and incentives for medical innovation. Forum for Health Economics and Policy: Vol.9: Iss.2 (Biomedical Research and the Economy, Article 4.
11. Jack W, Lanjouw J. 2005. Financing pharmaceutical innovation: how much should poor countries contribute? The World Bank Economic Review 19(1): 45-67.
12. Jena A, Philipson T. 2008. Cost effectiveness analysis and innovation. Journal of Health Economics 27: 1224-1236.
13. Jena A, Philipson T. 2013. Endogenous cost-effectiveness analysis and health care technology adoption. Journal of Health Economics 32: 172-180.
14. Lakdawalla D, Sood N. 2009. Innovation and the welfare effects of public drug insurance. Journal of Public Economics 93: 541-548.
15. Malueg D, Schwartz M. 1994. Parallel imports, demand dispersion, and international price discrimination. Journal of International Economics 37: 167-195.
16. National Institute for Health and Clinical Excellence. 2009. Appraising life-extending, end of life treatments. National Institute for Health and Clinical Excellence. Available from: http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf Accessed on 1st July 2013.
17. Office of Fair Trading. 2007. The Pharmaceutical Price Regulation Scheme: An OFT Market Study. OFT: London.